199 related articles for article (PubMed ID: 20658911)
1. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
Tomaszek SC; Huebner M; Wigle DA
Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
[No Abstract] [Full Text] [Related]
3. "Personalizing" therapy for non-small cell lung cancer.
D'Cunha J
Semin Thorac Cardiovasc Surg; 2010; 22(2):118-20. PubMed ID: 21092888
[TBL] [Abstract][Full Text] [Related]
4. Molecular prognostication of non-small cell lung cancer.
Tsao MS; Jablons DM
Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
[No Abstract] [Full Text] [Related]
5. Genomic medicine in non-small cell lung cancer: paving the path to personalized care.
Sriram KB; Larsen JE; Yang IA; Bowman RV; Fong KM
Respirology; 2011 Feb; 16(2):257-63. PubMed ID: 21044232
[TBL] [Abstract][Full Text] [Related]
6. Molecular biologic staging of lung cancer.
D'Amico TA
Ann Thorac Surg; 2008 Feb; 85(2):S737-42. PubMed ID: 18222207
[TBL] [Abstract][Full Text] [Related]
7. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
8. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.
Broët P; Camilleri-Broët S; Zhang S; Alifano M; Bangarusamy D; Battistella M; Wu Y; Tuefferd M; Régnard JF; Lim E; Tan P; Miller LD
Cancer Res; 2009 Feb; 69(3):1055-62. PubMed ID: 19176396
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
10. Translational research in lung cancer.
Chen Y; Okunieff P; Ahrendt SA
Semin Surg Oncol; 2003; 21(3):205-19. PubMed ID: 14508854
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data.
Mountzios G; Dimopoulos MA; Soria JC; Sanoudou D; Papadimitriou CA
Crit Rev Oncol Hematol; 2010 Aug; 75(2):94-109. PubMed ID: 19914087
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of p53 in non-small-cell lung cancer.
Komiya T; Hirashima T; Kawase I
Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of cyclin Dl expression in non-small cell lung cancer].
Dworakowska D
Pneumonol Alergol Pol; 2005; 73(3):297-300. PubMed ID: 16989170
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in non-small cell lung cancer.
Solan MJ; Werner-Wasik M
Semin Surg Oncol; 2003; 21(2):64-73. PubMed ID: 14508856
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
Dacic S
Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
[TBL] [Abstract][Full Text] [Related]
17. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
18. Which patients with stage III non-small cell lung cancer should undergo surgical resection?
Patel V; Shrager JB
Oncologist; 2005 May; 10(5):335-44. PubMed ID: 15851792
[TBL] [Abstract][Full Text] [Related]
19. Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics.
Harpole DH
Thorac Surg Clin; 2007 May; 17(2):167-73, viii. PubMed ID: 17626395
[TBL] [Abstract][Full Text] [Related]
20. miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer.
Gao W; Xu J; Shu YQ
Expert Rev Respir Med; 2011 Oct; 5(5):699-709. PubMed ID: 21955239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
